Drug Profile

Detalimogene voraplasmid - enGene

Alternative Names: Bladder cancer gene therapy - enGene; DDX^® intravesicle gene therapy - enGene; Detalimogene; EG-70

Latest Information Update: 01 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator enGene
Class Antineoplastics; Gene therapies; Immunotherapies
Mechanism of Action DDX58 protein inhibitors; Gene transference; Interleukin 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Bladder cancer
Research Urogenital cancer

Most Recent Events

25 Jun 2025 Detalimogene voraplasmid - enGene receives Regenerative Medicine Advanced Therapy (RMAT) status for Bladder cancer in USA
23 Oct 2024 Pharmacodynamics data from a preclinical trial in Bladder cancer presented at the 36^th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
26 Sep 2024 Preliminary efficacy and adverse events data from the phase I/II LENGEND trial in Bladder cancer released by enGene

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com